Details of the Drug Combinations

General Information of This Drug (ID: DM7KI4E)

Drug Name

Oblimersen DM7KI4E

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 3	[1]
Multiple myeloma	2A83	Phase 3	[1]
------------------------------------------------------------------------------------

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

7 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dacarbazine + Oblimersen	DCQFE08	Dacarbazine	Melanoma (Cell Line: .)	[2]
Dexamethasone + Oblimersen	DC8Q8XT	Dexamethasone	Multiple myeloma (Cell Line: .)	[2]
Fludarabine + Oblimersen	DCZVX50	Fludarabine	Acute leukaemia (Cell Line: .)	[2]
G-CSF + Oblimersen	DCM5KAR	G-CSF	Acute leukaemia (Cell Line: .)	[2]
Irinotecan + Oblimersen	DCTQPAH	Irinotecan	Metastatic colorectal cancer (Cell Line: .)	[2]
Paclitaxel + Oblimersen	DC5EN3P	Paclitaxel	Small-cell lung cancer (Cell Line: .)	[2]
Thalidomide + Oblimersen	DCZ691Y	Thalidomide	Multiple myeloma (Cell Line: .)	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DrugCom(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8269).
2	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.